New radioactive antibody could light up Hard-to-Treat cancers
NCT ID NCT07272642
First seen Jun 27, 2026 · Last updated Aug 13, 2026 · Updated 2 times
Summary
This early study tests a new radioactive antibody called NTH-2403 in 16 people with advanced colorectal, head and neck, lung, or triple-negative breast cancers. The antibody targets a protein found on cancer cells and their supporting cells, allowing doctors to see tumors on scans. The main goal is to check safety and how the agent spreads in the body, not to treat the cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- NTH-2403 (a radiolabeled antibody that binds to a protein on cancer cells and nearby cells, used for imaging)
- What this could lead to
- If successful, this could improve how doctors see and locate certain advanced solid tumors, and may pave the way for targeted treatment.
- What could go wrong
- This is a very early, small study (16 people) focused on safety and imaging, not treatment. It may not lead to effective therapy, and radiation exposure carries risks.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Icon Cancer Centre Hollywood
Nedlands, Western Australia, 6009, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Digital peer support: a new weapon against cancer treatment anxiety?
- Can a plasma beam stop colon polyps from coming back?
- A stitch in time: could a device make abdominal closure safer?
- Can we predict chemo brain before it happens?
- Can a new immunotherapy combo outsmart advanced lung cancer?
- Can targeted radiation boost Immunotherapy's power against head and neck cancer?